Combined Optical and Fluorescence Imaging for Breast Cancer Detection and Diagnosis

Jiang, Huabei; Ramesh, Sathappan; Bartlett, Matthew

doi:10.1615/critrevbiomedeng.v28.i34.40

Cited by 16 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has been studied extensively in the bioengineering literature. See for instance [Chang et al 1997;Contag et al 1998;Jang et al 2000]. Unlike higher-energetic markers used in classical nuclear imaging techniques such as single photon emission computed tomography (SPECT), positron emission tomography (PET), as well as magnetic resonance imaging (MRI), optical markers emit relatively low-frequency photons.…”

Section: Introductionmentioning

confidence: 99%

An inverse source problem in optical molecular imaging

Stefanov

Uhlmann

2008

APDE

102

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

An inverse source problem in optical molecular imaging

Stefanov

Uhlmann

2008

APDE

102

View full text Add to dashboard Cite

show abstract

“…Fluorescence tomography of whole animals and human organs is feasible in the near-IR region where the lower tissue attenuation allows the penetration of photons over several centimeters (13). Considerable literature exists in theoretical models of photon propagation in diffuse media but, despite original experimental studies with phantoms (14)(15)(16)(17), the in vivo demonstration of tomographic utility over existing imaging methods is limited. A few fiber-based systems for fluorescence tomography were recently reported (18)(19)(20) and the feasibility for in vivo imaging of proteases was demonstrated (21).…”

mentioning

confidence: 99%

Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V–Cy5.5 conjugate

Ntziachristos

Schellenberger

Ripoll

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

331

206

View full text Add to dashboard Cite

In vivo imaging of treatment responses at the molecular level could have a significant impact on the speed of drug discovery and ultimately lead to personalized medicine. Strong interest has been shown in developing quantitative fluorescence-based technologies with good molecular specificity and sensitivity for noninvasive 3D imaging through tissues and whole animals. We show herein that tumor response to chemotherapy can be accurately resolved by fluorescence molecular tomography (FMT) with a phosphatidylserinesensing fluorescent probe based on modified annexins. We observed at least a 10-fold increase of fluorochrome concentration in cyclophosphamide-sensitive tumors and a 7-fold increase of resistant tumors compared with control studies. FMT is an optical imaging technique developed to overcome limitations of commonly used planar illumination methods and demonstrates higher quantification accuracy validated by histology. It is further shown that a 3-fold variation in background absorption heterogeneity may yield 100% errors in planar imaging but only 20% error in FMT, thus confirming tomographic imaging as a preferred tool for quantitative investigations of fluorescent probes in tissues. Tomographic approaches are found essential for small-animal optical imaging and are potentially well suited for clinical drug development and monitoring. drug discovery ͉ quantification ͉ three-dimensional T he ability to noninvasively image molecular processes in vivo is an emerging reality with different reporter and detection approaches (1, 2). Molecular imaging has been heralded to lead to earlier detection than current anatomical imaging approaches, which typically detect late-stage abnormalities. Another important prospect of molecular imaging is the ability to examine and quantify treatment responses in vivo by monitoring specific primary molecules or downstream targets. Therapeutic efficacy could then be probed dynamically on timescales of hours to days. This ability is in contrast to the mainstay of today's healthcare with traditionally late end points of drug efficacy, a practice that often impairs prompt revision and exclusion of ineffective treatment strategies with potentially lethal results.Drug-induced apoptosis is considered a generic biomarker of monitoring the effects of chemotherapeutic drugs (3), antihormonal therapeutics (4), or antiangiogenic therapies (5). Of several different detection methods, optical imaging is emerging as an important alternative to techniques using ionizing radiation and offers the advantages of stable fluorochromes, easier to perform chemistries, and portable and cost-effective imaging practices. Laxman et al. (6), for example, developed a recombinant luciferase reporter molecule that amplifies luminescence in apoptotic cells by specific cleavage of a Asp-Glu-Val-Asp fragment by caspase 3, which can be used in animal studies. Fluorescence detection using an annexin V probe tagged with a cyanine dye has been demonstrated by Schellenberger et al. (7) and Petrovsky et al. (8). Imagin...

show abstract

“…Photon migration in tissue is known to behave as a diffusive process and can be characterized using the photon diffusion equation. [7][8][9][10][11][12][13] During this migration, photons experience absorption and scattering events. The probabilities for the occurrence of these events are described by absorption and scattering coefficients.…”

Section: Diffuse Correlation Spectroscopymentioning

confidence: 99%

“…Endogenous tumor-to-normal contrasts available to NIRS include: tissue absorption; scattering; concentrations of oxy-, deoxy-, and total-hemoglobin, water and lipids; and blood oxygen saturation. [7][8][9][10][11][12][13][14][15] A relatively new dynamic NIR technique, namely diffuse correlation spectroscopy (DCS) 16,17 or diffuse wave spectroscopy (DWS), [18][19][20] has been developed which can directly measure the motions of red blood cells in biological tissues while also maintaining all the advantages of NIRS. DCS flow measurements are accomplished by monitoring speckle fluctuations of photons induced by the moving scatterers in tissues.…”

Section: Introductionmentioning

confidence: 99%

Near-infrared diffuse correlation spectroscopy in cancer diagnosis and therapy monitoring

2012

J. Biomed. Opt.

View full text Add to dashboard Cite

Abstract. A novel near-infrared (NIR) diffuse correlation spectroscopy (DCS) for tumor blood flow measurement is introduced in this review paper. DCS measures speckle fluctuations of NIR diffuse light in tissue, which are sensitive to the motions of red blood cells. DCS offers several attractive new features for tumor blood flow measurement such as noninvasiveness, portability, high temporal resolution, and relatively large penetration depth. DCS technology has been utilized for continuous measurement of tumor blood flow before, during, and after cancer therapies. In those pilot investigations, DCS hemodynamic measurements add important new variables into the mix for differentiation of benign from malignant tumors and for prediction of treatment outcomes. It is envisaged that with more clinical applications in large patient populations, DCS might emerge as an important method of choice for bedside management of cancer therapy, and it will certainly provide important new information about cancer physiology that may be of use in diagnosis.

show abstract

Combined Optical and Fluorescence Imaging for Breast Cancer Detection and Diagnosis

Cited by 16 publications

References 0 publications

An inverse source problem in optical molecular imaging

An inverse source problem in optical molecular imaging

Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V–Cy5.5 conjugate

Near-infrared diffuse correlation spectroscopy in cancer diagnosis and therapy monitoring

Contact Info

Product

Resources

About